- Home
- BBIO vs RARE Comparison
BBIO vs RARE Comparison
Compare BBIO & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- RARE
- Stock Information
- Founded
- BBIO 2015
- RARE 2010
- Country
- BBIO United States
- RARE United States
- Employees
- BBIO N/A
- RARE N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- BBIO Health Care
- RARE Health Care
- Exchange
- BBIO Nasdaq
- RARE Nasdaq
- Market Cap
- BBIO 5.1B
- RARE 5.2B
- IPO Year
- BBIO 2019
- RARE 2014
- Fundamental
- Price
- BBIO $26.49
- RARE $43.98
- Analyst Decision
- BBIO Strong Buy
- RARE Strong Buy
- Analyst Count
- BBIO 13
- RARE 14
- Target Price
- BBIO $47.92
- RARE $88.43
- AVG Volume (30 Days)
- BBIO 2.7M
- RARE 717.6K
- Earning Date
- BBIO 11-12-2024
- RARE 02-13-2025
- Dividend Yield
- BBIO N/A
- RARE N/A
- EPS Growth
- BBIO N/A
- RARE N/A
- EPS
- BBIO N/A
- RARE N/A
- Revenue
- BBIO $217,765,000.00
- RARE $522,745,000.00
- Revenue This Year
- BBIO $2,648.47
- RARE $27.36
- Revenue Next Year
- BBIO N/A
- RARE $18.61
- P/E Ratio
- BBIO N/A
- RARE N/A
- Revenue Growth
- BBIO 2209.77
- RARE 27.44
- 52 Week Low
- BBIO $21.62
- RARE $37.02
- 52 Week High
- BBIO $44.32
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- BBIO 49.05
- RARE 33.50
- Support Level
- BBIO $25.34
- RARE $41.45
- Resistance Level
- BBIO $28.15
- RARE $50.00
- Average True Range (ATR)
- BBIO 1.33
- RARE 1.83
- MACD
- BBIO -0.24
- RARE -0.31
- Stochastic Oscillator
- BBIO 24.73
- RARE 26.55
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.